Lunai Bioworks Launches Pathfinder Consortium To Accelerate Chemical Antidote Development To 3-Year Timeline

Lunai Bioworks, through its subsidiary BioSymetrics, has launched the Pathfinder Consortium to expedite the development of chemical antidotes for emerging threats, aiming to reduce the timeline to approximately three years. This national alliance will integrate various U.S. chemical warfare preparedness resources, which have historically operated in silos, into a unified framework designed for rapid execution and efficiency. The consortium's model includes a streamlined regulatory pathway that allows for quicker validation and testing processes, including efficacy demonstrations and safety studies.